CD Protein Inhibitors 

  Products    Products    Diseases    News 


«12...89101112131415161718...39313932»
  • ||||||||||  Darzalex (daratumumab) / J&J, Blenrep (belantamab mafodotin-blmf) / GSK
    A deeper look into infections among myeloma patients treated with Daratumumab or Belantamab mafodotin (Exhibit Hall, Pavilion 3) -  Sep 26, 2024 - Abstract #IMW2024IMW_664;    
    Nevertheless, infections including CMV reactivation are frequent adverse events associated with antiCD38 but rare among anti-BCMA immunotherapies utilized in analysis. Intravenous Immunoglobulin use per treatment year was less among patients treated with Belantamab.
  • ||||||||||  Ninlaro (ixazomib) / Takeda
    IXAZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS  (Exhibit Hall, Pavilion 3) -  Sep 26, 2024 - Abstract #IMW2024IMW_662;    
    Similar outcomes were also reported in RR MM group of patients by other RWE analyses. There are some discrepancies between RWE data and data reported in clinical trials.
  • ||||||||||  Darzalex Faspro (daratumumab and hyaluronidase-fihj) / J&J
    Stem Cell (SC) Yield and Transplant with Daratumumab  (Exhibit Hall, Pavilion 3) -  Sep 26, 2024 - Abstract #IMW2024IMW_649;    
    P3
    Despite D-VRd ind therapy resulting in a lower SC yield compared to VRd alone, SC mobilization and collection remained feasible with D-VRd ind. Overall, successful transplantation was achieved in pts with TE NDMM when combining DARA with VRd ind and when performed after Cycle 6.
  • ||||||||||  Darzalex (daratumumab) / J&J
    A retrospective comparison of single versus tandem transplant in newly diagnosed Multiple Myeloma: a real-world study (Exhibit Hall, Pavilion 3) -  Sep 26, 2024 - Abstract #IMW2024IMW_632;    
    Indeed, the introduction of Daratumumab and, more recently, the first trials exploring the use of CAR-T products as alternative to ASCT has reduced the absolute need to transplant patients with NDMM. Even more, numerous studies demonstrated the toxicity of tandem myeloablative treatment regarding the bone marrow and the potential risk of developing mutations and secondary neoplasms.
  • ||||||||||  Darzalex Faspro (daratumumab and hyaluronidase-fihj) / J&J
    Cryoglobulinemic vasculitis with gangrene as an initial presentation of Multiple myeloma (Exhibit Hall, Pavilion 3) -  Sep 26, 2024 - Abstract #IMW2024IMW_628;    
    Subcutaneous Daratumumab , Bortezomib, Cyclophosphamide and Dexamethasone was given as per standard protocol for the myeloma clone. Our case highlights one of the rare presenting symptom of patient with Multiple myeloma and highlights the role of prompt intervention and multi disciplinary approach to salvage such patients who have a high risk of fatal complications.
  • ||||||||||  Darzalex (daratumumab) / J&J, Ninlaro (ixazomib) / Takeda, Sarclisa (isatuximab-irfc) / Sanofi
    Systemic Treatment Outcomes in Relapsed or Refractory POEMS Syndrome  (Exhibit Hall, Pavilion 3) -  Sep 26, 2024 - Abstract #IMW2024IMW_593;    
    Therapies used for R/R MM are efficacious. 2L line ASCT resulted in deep and durable responses.
  • ||||||||||  Darzalex (daratumumab) / J&J
    A unique presentation of Light Chain Deposition Disease: kidney disease with no proteinuria (Exhibit Hall, Pavilion 3) -  Sep 26, 2024 - Abstract #IMW2024IMW_578;    
    The kidney injury is primarily caused by the abnormal deposition or activity of monoclonal proteins in the kidney, including, light chains, heavy chains, or intact immunoglobulins, produced by small, nonmalignant or premalignant plasma cell or B cell clones. Patients with LCDD usually have abnormal FLC ratio, hematuria and proteinuria ?1.5g/day.
  • ||||||||||  Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
    Ibrutinib plus rituximab versus ibrutinib monotherapy in patients with Waldenstr (Exhibit Hall, Pavilion 3) -  Sep 26, 2024 - Abstract #IMW2024IMW_573;    
    P2, P3
    This case had a late diagnose of systemic amyloidosis with GI, cardiac, hepatic and renal involvement. Based on this pooled analysis of patient-level data from three prospective studies, the addition of rituximab to ibrutinib was associated with superior 30-month PFS rates in WM patients with CXCR4 mutations and in patients with high IPSSWM scores.
  • ||||||||||  Darzalex (daratumumab) / J&J
    IMPACT OF THE ADDITION OF DARATUMUMAB TO THE FRONTLINE TREATMENT OF PATIENTS WITH AL AMYLOIDOSIS (Exhibit Hall, Pavilion 3) -  Sep 26, 2024 - Abstract #IMW2024IMW_571;    
    Treatment with Daratumumab should be considered a therapy of choice in AL amyloidosis. The addition of daratumumab to PI in the frontline treatment of AL amyloidosis improved HR and resulted into deeper and faster responses and, subsequently into a significant benefit in PFS for all patients, even those at stage III-IV.
  • ||||||||||  Talvey (talquetamab-tgvs) / J&J
    Defining the Rates of Cytokine Release Syndrome Associated with Talquetamab Step-up Doses. (Exhibit Hall, Pavilion 3) -  Sep 26, 2024 - Abstract #IMW2024IMW_552;    
    Our real-world data indicated that the Talq FFD was well tolerated, characterized by a significantly low incidence/severity of CRS events. Reducing length of hospital stay with the Talq step-up dosing schedule, and administration of Talq FFD in outpatient settings could be considered in clinical practice.
  • ||||||||||  Darzalex (daratumumab) / J&J
    Real-World Treatment Tendencies in Multiple Myeloma: Analysis of Drug Utilization Over Time in Brazil and Argentina (Exhibit Hall, Pavilion 3) -  Sep 26, 2024 - Abstract #IMW2024IMW_545;    
    The treatment landscape for MM in Brazil and Argentina followed similar trends, with an increase in IMiD and monoclonal antibody use and a reduction in chemotherapy and PI use. Understanding the current treatment patterns and trends in Brazil and Argentina will help to raise awareness, identify unmet needs, and optimize the therapeutic strategies for MM.
  • ||||||||||  Darzalex (daratumumab) / J&J
    Bone Marrow Immune Ecosystem Shapes Acquired Daratumumab Resistance in Plasma Cell Myeloma (Exhibit Hall, Pavilion 3) -  Sep 26, 2024 - Abstract #IMW2024IMW_539;    
    Mechanisms underlying acquired daratumumab resistance are complex involving crosstalk between immune cells and neoplastic plasma cells. Increased activation of MYC may be an important mechanism promoting acquired daratumumab resistance.
  • ||||||||||  Darzalex (daratumumab) / J&J
    Mapping Racial Disparities in Immune Cell Dysregulations and Multiple Myeloma Outcomes Using Single-Cell Profiling (Exhibit Hall, Pavilion 3) -  Sep 26, 2024 - Abstract #IMW2024IMW_525;    
    Some of these alterations in Black populations, such as adaptive NK cells, have been associated with either decreased relapse, or stronger responses to therapies such as Daratumumab and ASCT, which historically have been vastly underutilized in the US Black population, especially in the first lines of therapy. Overall, this indicates that there are some alterations in the immune microenvironment with respect to self-identified race.